Equities analysts predict that Kadmon Holdings Inc (NYSE:KDMN) will announce ($0.16) earnings per share for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Kadmon’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.17). Kadmon reported earnings of ($0.21) per share in the same quarter last year, which indicates a positive year over year growth rate of 23.8%. The firm is expected to report its next earnings results on Thursday, August 8th.

According to Zacks, analysts expect that Kadmon will report full-year earnings of ($0.54) per share for the current year, with EPS estimates ranging from ($0.57) to ($0.50). For the next year, analysts anticipate that the business will report earnings of ($0.69) per share, with EPS estimates ranging from ($0.84) to ($0.54). Zacks’ earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Kadmon.

Kadmon (NYSE:KDMN) last announced its earnings results on Thursday, March 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.18). Kadmon had a negative return on equity of 91.12% and a negative net margin of 2,487.49%.

A number of research analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Kadmon from a “strong sell” rating to a “hold” rating in a research report on Wednesday. Citigroup upgraded shares of Kadmon from a “neutral” rating to a “buy” rating and set a $2.77 target price on the stock in a research report on Tuesday, February 26th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 target price on shares of Kadmon in a research report on Tuesday, March 12th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $8.36.

Several institutional investors have recently modified their holdings of KDMN. Amalgamated Bank bought a new stake in shares of Kadmon during the 4th quarter worth approximately $25,000. Capital Investment Advisors LLC bought a new stake in shares of Kadmon during the 4th quarter worth approximately $26,000. IFP Advisors Inc lifted its holdings in shares of Kadmon by 54.5% during the 4th quarter. IFP Advisors Inc now owns 25,500 shares of the company’s stock worth $49,000 after acquiring an additional 9,000 shares during the period. Metropolitan Life Insurance Co. NY lifted its holdings in shares of Kadmon by 356.6% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 26,251 shares of the company’s stock worth $55,000 after acquiring an additional 20,502 shares during the period. Finally, BNP Paribas Arbitrage SA bought a new stake in shares of Kadmon during the 1st quarter worth approximately $55,000. 65.40% of the stock is owned by institutional investors.

Shares of NYSE:KDMN traded up $0.05 on Thursday, reaching $2.29. 298,505 shares of the company’s stock were exchanged, compared to its average volume of 856,810. Kadmon has a twelve month low of $1.88 and a twelve month high of $4.39. The company has a debt-to-equity ratio of 0.60, a quick ratio of 3.85 and a current ratio of 3.89.

Kadmon Company Profile

Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.

Featured Story: How to interpret the current ratio

Get a free copy of the Zacks research report on Kadmon (KDMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.